Evidence map›Paper›PMID 35127393›Full record

ArticleActa pharmaceutica Sinica. B2022

A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer.

Dandan Sun, Yifang Zou, Liu Song, Shulan Han, Hao Yang, Di Chu, Yun Dai, Jie Ma, Caitriona M O'Driscoll, Zhuo Yu and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 2 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 178 citations in OpenAlex.

  1. Pooled it
  2. Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Dandan SunSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Yifang ZouSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Liu SongSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Shulan HanSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Hao YangSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Di ChuSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Yun DaiLaboratory of Cancer Precision Medicine, The First Hospital of Jilin University, Changchun 130021, China.
Jie MaSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Caitriona M O'DriscollPharmacodelivery Group, School of Pharmacy, University College Cork, Cork T12 YT20, Ireland.
Zhuo YuDepartment of Hepatopathy, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Jianfeng GuoSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Jilin University · CNShanghai University of Traditional Chinese Medicine · CNUniversity College Cork · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune checkpoint blockade therapy has profoundly revolutionized the field of cancer immunotherapy. However, despite great promise for a variety of cancers, the efficacy of immune checkpoint inhibitors is still low in colorectal cancer (CRC). This is mainly due to the immunosuppressive feature of the tumor microenvironment (TME). Emerging evidence reveals that certain chemotherapeutic drugs induce immunogenic cell death (ICD), demonstrating great potential for remodeling the immunosuppressive TME. In this study, the potential of ginsenoside Rg3 (Rg3) as an ICD inducer against CRC cells was confirmed using

Indexed as

ATF6, activating transcription factor 6ATP, adenosine triphosphateChemotherapyCI, combination indexColorectal cancerCombination therapyCRC, colorectal cancerCRT, calreticulinCTLA-4, cytotoxic T lymphocyte antigen 4CXCL10, C-X-C motif chemokine 10CXCL9, C-X-C motif chemokine 9DAMPs, damage-associated molecular patternsDCs, dendritic cellsECL, enhanced chemiluminescenceEE, encapsulation efficiencyER, endoplasmic reticulumFA, folateHMGB1, high-mobility group box 1ICD, immunogenic cell deathIFN-γ, interferon-gammaIL-10, interleukin-10IL-12, interleukin-12IL-4, interleukin-4IL-6, interleukin-6Immunogenic cell deathImmunotherapyIRE1, inositol-requiring enzyme 1LC, loading capacityMDSCs, myeloid derived suppressor cellsMMR, mismatch repairMR, molar ratioNAC, N-acetyl-l-cysteineNano drug delivery systemNP, nanoparticlePD-L1, programmed death-ligand 1PEG, polyethylene glycolPERK, PKR-like ER kinasePFA, paraformaldehydep-IRE1, phosphorylation of IRE1p-PERK, phosphorylation of PERKPVDF, polyvinylidene fluorideQTN, quercetinReactive oxygen speciesROS, reactive oxygen speciesTAAs, tumor-associated antigensTME, tumor microenvironmentTumor microenvironmentUPR, unfolded protein response

Identifiers

PMID35127393
PMCPMC8799998
OpenAlexW3174442355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.